Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) – Pipeline Review, H2 2017’, provides in depth analysis on Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Metabolic Disorders, Gastrointestinal, Musculoskeletal Disorders and Central Nervous System under development targeting Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP)

The report reviews Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics and enlists all their major and minor projects

The report assesses Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Adocia SAS

AstraZeneca Plc

Eli Lilly and Co

Neurimmune Holding AG

Nordic Bioscience A/S

Prothena Corp Plc

reMYND NV

Zealand Pharma AS

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Overview 7

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Therapeutics Development 8

Products under Development by Stage of Development 8

Products under Development by Therapy Area 9

Products under Development by Indication 10

Products under Development by Companies 11

Products under Development by Universities/Institutes 14

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Therapeutics Assessment 16

Assessment by Mechanism of Action 16

Assessment by Route of Administration 18

Assessment by Molecule Type 20

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Companies Involved in Therapeutics Development 22

Adocia SAS 22

AstraZeneca Plc 22

Eli Lilly and Co 22

Neurimmune Holding AG 23

Nordic Bioscience A/S 23

Prothena Corp Plc 24

reMYND NV 24

Zealand Pharma AS 25

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Drug Profiles 26

(insulin human + pramlintide acetate) - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

(insulin lispro + pramlintide) - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

AC-253 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

DACRA-042 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

DACRA-089 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

KBP-056 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

KBP-088 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Monoclonal Antibodies for Type 2 Diabetes - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

NI-203 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

ReS-39 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Synthetic Peptides to Target IAPP for Obesity and Diabetes - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

UGP-302 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

ZP-4982 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

ZP-5461 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Dormant Products 44

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Discontinued Products 45

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Product Development Milestones 46

Featured News & Press Releases 46

May 11, 2017: Zealand Pharma discloses amylin as the biological target under their 2014 agreement with Boehringer Ingelheim 46

Jan 05, 2017: Adocia Launches New Multi-Hormonal Combination Project For Treatment Of Type 1 Diabetes 46

Jun 08, 2016: Zealand presents new data on proprietary preclinical peptide drug candidates at the 76th Annual American Diabetes Associations Scientific Sessions 47

Aug 19, 2015: Nordic Bioscience Announces Successful Completion of Phase I study for KBP-042 48

May 05, 2014: reMYND’s novel diabetes treatment prevents - and even reverses - disease progression in pre-clinical diabetes models 48

Apr 10, 2013: Centennial Lecture features research on restoring memory and movement 49

Dec 11, 2012: University Of Alberta Medical Researchers Make Key Discovery In Fight Against Alzheimer's Disease 50

Aug 15, 2012: Unigene Labs And Nordic Bioscience Announce Preliminary Selection Of Lead Compound For Treatment Of Type 2 Diabetes 51

Appendix 53

Methodology 53

Coverage 53

Secondary Research 53

Primary Research 53

Expert Panel Validation 53

Contact Us 53

Disclaimer 54

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Indication, H2 2017 10

Number of Products under Development by Companies, H2 2017 11

Products under Development by Companies, H2 2017 12

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 13

Number of Products under Investigation by Universities/Institutes, H2 2017 14

Products under Investigation by Universities/Institutes, H2 2017 15

Number of Products by Stage and Mechanism of Actions, H2 2017 17

Number of Products by Stage and Route of Administration, H2 2017 19

Number of Products by Stage and Molecule Type, H2 2017 21

Pipeline by Adocia SAS, H2 2017 22

Pipeline by AstraZeneca Plc, H2 2017 22

Pipeline by Eli Lilly and Co, H2 2017 23

Pipeline by Neurimmune Holding AG, H2 2017 23

Pipeline by Nordic Bioscience A/S, H2 2017 24

Pipeline by Prothena Corp Plc, H2 2017 24

Pipeline by reMYND NV, H2 2017 25

Pipeline by Zealand Pharma AS, H2 2017 25

Dormant Projects, H2 2017 44

Discontinued Products, H2 2017 45

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Indications, H2 2017 10

Number of Products by Mechanism of Actions, H2 2017 16

Number of Products by Stage and Mechanism of Actions, H2 2017 16

Number of Products by Routes of Administration, H2 2017 18

Number of Products by Stage and Routes of Administration, H2 2017 18

Number of Products by Molecule Types, H2 2017 20

Number of Products by Stage and Molecule Types, H2 2017 20

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports